China’s NMPA grants priority review status for Ocumension’s Zerviate NDA
Pharmaceutical Technology
MAY 1, 2023
The NDA is supported by the data package licensed to Ocumension by Nicox as well as the Phase III clinical trial in China. Nicox granted exclusive license to Ocumension to develop and commercialise Zerviate in China and most of the Southeast Asian markets.
Let's personalize your content